Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.67 |
| ▸ | GPR183 | P32249 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.49 |
| ▸ | ITGAL | P20701 | 2/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414316 | 1.00 | MIF (0.67) | MIFGPR183HDAC3HDAC4HDAC1 | |
| SCHEMBL1233597 | 1.00 | MIF (0.67) | MIFGPR183HDAC3HDAC4HDAC1 | |
| SCHEMBL30278657 | 1.00 | MIF (0.67) | MIFGPR183HDAC3HDAC4HDAC1 | |
| SCHEMBL1674366 | 0.87 | MIF (0.54) | MIFGPR183MAPTITGB2ICAM1 | |
| SCHEMBL4925948 | 0.87 | MIF (0.54) | MIFGPR183MAPTITGB2ICAM1 | |
| SCHEMBL7828225 | 0.86 | MIF (0.51) | MIFGPR183HDAC3HDAC4HDAC1 | |
| SCHEMBL7828224 | 0.86 | MIF (0.51) | MIFGPR183HDAC3HDAC4HDAC1 | |
| SCHEMBL30310600 | 0.86 | HDAC3 (0.50) | MIFGPR183HDAC3HDAC4HDAC1 | |
| SCHEMBL22046677 | 0.86 | HDAC3 (0.50) | MIFGPR183HDAC3HDAC4HDAC1 | |
| SCHEMBL4608128 | 0.84 | HDAC3 (0.49) | MIFGPR183HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747059-A1 | PERVAPORATION COMPOSITE MEMBRANES | McMaster University (CA) | 2007-01-31 | — | — | EP | claimed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | claimed |
| WO-2005102503-A1 | PERVAPORATION COMPOSITE MEMBRANES | MCMASTER UNIVERSITY (CA) | 2005-11-03 | — | — | WO | claimed |
| EP-4263502-B1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2024-12-25 | — | — | EP | disclosed |
| US-12060333-B2 | Aminocarbamoyl compounds for the treatment of viral infections | HOFFMANN-LA ROCHE INC. (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240083845-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-03-14 | — | — | US | disclosed |
| CN-117136178-A | SARS-COV-2 Mpro inhibitor compounds | 赫帕雷斯治疗有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-4263502-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116438160-A | Carbamoyl compounds for the treatment of viral infections | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4204393-A1 | AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022129953-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| US-6562844-B2 | Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-6531470-B1 | Antimicrobial compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-11 | — | — | US | disclosed |
| WO-2002026696-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| US-6239152-B1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2000008023-A1 | CONDENSED TRICYCLIC PIPERIDINES HAVING ANTI-CONVULSANT ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-02-17 | — | — | WO | disclosed |
| EP-0759026-B1 | AMIDE DERIVATIVES AND THEIR THERAPEUTIC USE | WELLCOME FOUND (GB) | 1999-08-18 | — | — | EP | disclosed |
| US-5708033-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS OR ANALGESICS | GLAXO WELLCOME INC. (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0759026-A1 | AMIDE DERIVATIVES AND THEIR THERAPEUTIC USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-02-26 | — | — | EP | disclosed |
| WO-1995030645-A1 | AMIDE DERIVATIVES AND THEIR THERAPEUTIC USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083845-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | ACE2, SARS1, ACE | MIF 718/4885GPR183 1346/4885HDAC3 791/4885 |
| US-12060333-B2 | Aminocarbamoyl compounds for the treatment of viral infections | SARS1, BCAT1, SLC1A5 | MIF 4599/4885GPR183 954/4885HDAC3 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.